Keros Therapeutics, Inc. (KROS) 8-K Current Report — March 4, 2026
Filed: March 4, 2026
Health Care
Pharmaceutical PreparationsKeros Therapeutics, Inc. (KROS) 8-K current report filed with SEC EDGAR on March 4, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 7.01: Regulation FD Disclosure
Keros Therapeutics, Inc. 8-K Mar 4, 2026 Event Analysis
Item 7.01 · Regulation FD Disclosure
- • Updated investor presentation filed March 4, 2026 — signals potential catalysts or strategic updates worth reviewing in Exhibit 99.1
- • Furnished (not filed) under Reg FD — limits legal liability but ensures broad, simultaneous investor access to material information
Other Keros Therapeutics, Inc. 8-K Filings
Get deeper insights on Keros Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.